Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.
Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA, Cortés J, Saura C, Arribas J. Nadal-Serrano M, et al. Among authors: saura c. Cancers (Basel). 2020 Mar 13;12(3):670. doi: 10.3390/cancers12030670. Cancers (Basel). 2020. PMID: 32183023 Free PMC article.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzmán M, Rodríguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstmann R, Prat A, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V. Gris-Oliver A, et al. Among authors: saura c. Clin Cancer Res. 2020 Jul 15;26(14):3720-3731. doi: 10.1158/1078-0432.CCR-19-3324. Epub 2020 Mar 27. Clin Cancer Res. 2020. PMID: 32220884 Free PMC article.
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. Sánchez-Guixé M, et al. Among authors: saura c. Clin Cancer Res. 2022 Jan 1;28(1):137-149. doi: 10.1158/1078-0432.CCR-21-1810. Epub 2021 Sep 30. Clin Cancer Res. 2022. PMID: 34593528
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A, Gonzalez NS, Pimentel I, Suñol A, Zamora E, Ortiz C, Espinosa-Bravo M, Peg V, Vivancos A, Saura C, Villacampa G, Oliveira M. Papakonstantinou A, et al. Among authors: saura c. Cancer Treat Rev. 2022 Mar;104:102362. doi: 10.1016/j.ctrv.2022.102362. Epub 2022 Feb 18. Cancer Treat Rev. 2022. PMID: 35219090 Review.
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ciriaco N, Zamora E, Escrivá-de-Romaní S, Miranda Gómez I, Jiménez Flores J, Saura C, Sloane H, Starus A, Fredebohm J, Georgieva L, Speight G, Jones F, Ramón Y Cajal S, Espinosa-Bravo M, Peg V. Ciriaco N, et al. Among authors: saura c. Ther Adv Med Oncol. 2022 Nov 29;14:17588359221139601. doi: 10.1177/17588359221139601. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36479470 Free PMC article.
227 results